|
Home > Resources > Featured Editorial
Plavix May Treat Dog Disease July 16, 2010
Companion animals that have a long-term need for anticoagulant drug therapies may soon find help in a top-selling antiplatelet drug marketed to humans: clopidogrel, commonly known as Plavix.
Researchers in the Univ. of Georgia College of Veterinary Medicine have found that clopidogrel may be a safe and effective treatment for dogs that need long-term anticoagulant (blood clotting) therapy. In addition, it may offer a safe alternative to NSAYSs for treating dogs at risk of thromboembolism because of concurrent therapeutic use of corticosteroids.
Other than aspirin, there are currently no approved antiplatelet drug therapies available to treat companion animals with known or suspected hypercoagulability. Anticoagulants such as heparin, which must be administered by injection, are often used instead, btu researchers say many animal owners are reluctant to administer injectable drugs to their pets.
In addition, critically ill dogs are at risk for thromboembolic disease, including pulmonary and aortic thromboembolism, both of which are associated with severe illness and death. Dogs that develop thrombosis and are subsequently treated with thrombolytic agents are at a substantial risk of hemorrhage or metabolic instability.
Clopidogrel, which is only available as an oral therapy, has been safely administered to cats, rabbits and calves, but little has been published about its effects in dogs.
In a study of healthy dogs, researchers found most had a significant inhibition of platelet function within three hours of receiving clopidogrel. All of the dogs in the study tolerated the drug well and showed no evidence of bruising, hemorrhage or other adverse effects. In addition, platelet activity returned to normal levels within approximately seven days after the drug was discontinued, which is similar to the response in humans.
The researchers caution that their study only provides data on the effectiveness of clopidogrel in healthy dogs, and not on dogs that are critically ill or receiving other drugs. Further pharmacokinetic and pharmacodynamic studies in critically ill canine patients are planned, in addition to studies evaluating this drug in healthy horses.
Source: Univ. of Georgia
|
|
|
|
|
|
